Related Issuers
by Stephen Carter
May 07, 2021 7:34 AM ET
Chrome Bidco/Holdco (Cerba HealthCare) EUR745m 144A/Reg S 2-part. (Corp ratings B2/B (stable/stable). Via DB (physical)/GS/Natixis/UBS jt lead books/BNP/CA/HSBC/JPM/Mizuho/Nomura/UniCredit jt books. No reg rights. List Lux. NY law.
- Chrome Bidco SAS EUR420m sr sec notes due 2028 (7y). NC3 (MWC T+50bp). Equity claw: 3y 40%. Special call: 10% per year the first 3 years at 103. Ratings TBC (sr sec term loan B1/B).
- Chrome Holdco SAS EUR325m sr unsec notes due 2029 (8y). NC3 (MWC T+50bp). Equity claw: 3y 40%. Ratings TBC.
Virtual meetings Mon-Weds (investor call at 10am UKT Mon). UOP: along with EUR1.525bn term loan B, to fund the acquisition of a majority stake in Cerba by EQT from Partners Group for EUR2.82bn and repay EUREUR240m existing notes and EUR1.342bn existing sr credit facilities. Canada's PSP Investments will retain its minority ownership stake. EQT will make an equity contribution of EUR1.229bn. Biz: an international network of medical biological laboratories providing medical diagnostic services. HQ: Issy-les-Moulineaux, France. (Acquisition announced 03/30/21).